Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASC30 Phase 1 in obesity
NCT06680440Phase 1Completed
- Sponsor
- Ascletis Pharma Inc.
- Start
- Aug 2024
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ASC30 in obesity (8 cohorts), sponsored by Ascletis Pharma Inc. Primary endpoints: Incidence of AEs and SAEs (SAD) at Day 8 and Incidence of AEs and SAEs (MAD) at Day 28. Started Aug 2024; status: completed.
02
Drugs
ASC30
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06680440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06680440.